AbbVie Inc.

AbbVie Inc.

106.06
BRL
-6.56
(-5.82%)
2.03EPS
41.67P/E
2.23TMarket Cap
Feb 03Next Earn

Total Valuation

BRL

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh carries a market capitalization of 2.23T, placing it among publicly traded companies globally. Its enterprise value stands at 2.60T, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap2.23T
Enterprise Value2.60T

Important Dates

AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh's next confirmed earnings release is scheduled for February 3, 2027.

Earnings Date2/3/2027

Share Statistics

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh has 26.29B shares outstanding.

Shares Outstanding26.29B

Valuation Ratios

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh trades at a trailing price-to-earnings ratio of 41.67. The price-to-sales ratio is 6.53, and the price-to-book ratio stands at -94.04.

PE Ratio41.67
PS Ratio6.53
PB Ratio-94.04
P/TBV Ratio-4.35
P/FCF Ratio22.91
P/OCF Ratio21.45

Enterprise Valuation

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh trades at an EV/EBITDA multiple of 17.34 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.59 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 23.60 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh trades at an EV/FCF ratio of 23.55, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 2.60T versus a market cap of 2.23T, with the gap driven by net debt and cash on the balance sheet.

EV / Sales7.59
EV / EBITDA17.34
EV / EBIT23.60
EV / FCF23.55

Financial Position

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -1,782.79, indicating conservative leverage, while an interest coverage ratio of 9.70 demonstrates adequate ability to service its debt obligations.

Current Ratio0.87
Quick Ratio0.56
Debt / Equity-1,782.79
Debt / EBITDA2.80
Interest Coverage9.70

Financial Efficiency

BRL

These figures cover the twelve months ended September 30, 2026. Return on invested capital (ROIC) comes in at 24.06 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 7.35, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 17.88, useful for judging operating efficiency across full business cycles. The company generates approximately 6.00M in revenue per employee across its workforce of 57,000.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.39 indicates how many times AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)7.35
Return on Invested Capital (ROIC)24.06
Return on Capital Employed (ROCE)17.88
Revenue Per Employee6.00M
Employee Count57,000.00
Inventory Turnover3.39

Taxes

BRL

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh recorded 12.78B in income tax expense. That works out to an effective tax rate of 19.24, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 66.41B, leaving 53.60B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax12.78B
Effective Tax Rate19.24

Stock Price Statistics

BRL

As of the close on November 16, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh's stock has gained approximately 48.90% over the past 52 weeks. The 50-day moving average sits at 90.37, while the 200-day moving average is 77.67.

52-Week Price Change48.90%
50-Day Moving Average90.37
200-Day Moving Average77.67

Income Statement

BRL

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh generated 342.12B in revenue and converted that into 53.60B in net income, yielding earnings per share of 2.03. EBITDA reached 149.77B, while operating income came in at 123.08B.

Revenue342.12B
Gross Profit252.22B
Operating Income123.08B
Pretax Income66.41B
Net Income53.60B
EBITDA149.77B
EBIT110.04B
Earnings Per Share (EPS)2.03

Balance Sheet

BRL

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh holds 55.84B in cash and equivalents against 419.28B in total debt, resulting in a net debt position of 363.44B. Total book value stands at -23.75B, with working capital of -29.14B providing operational flexibility.

Cash & Cash Equivalents55.84B
Total Debt419.28B
Net Debt363.44B
Equity (Book Value)-23.75B
Book Value Per Share-0.90
Working Capital-29.14B

Cash Flow

BRL

AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh produced 104.11B in operating cash flow over the twelve months ended September 30, 2026. After subtracting -6.31B in capital expenditures, free cash flow totaled 97.80B - equivalent to 3.72 per share.

Operating Cash Flow104.11B
Capital Expenditures-6.31B
Free Cash Flow97.80B
FCF Per Share3.72

Margins

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh posted a gross margin of 73.72, reflecting its pricing power and cost economics. The operating margin of 35.98 and net profit margin of 15.67 provide insight into operational efficiency.

Gross Margin73.72
Operating Margin35.98
Pretax Margin19.41
Profit Margin15.67
EBITDA Margin43.78

Dividends & Yields

BRL

Over the twelve months ended September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh paid dividends of 2.39 per share. The dividend payout ratio of 117.23 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 4.37, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 0.34, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh shareholders.

Dividend Per Share2.39
Payout Ratio117.23
Shareholder Yield0.34
FCF Yield4.37

Stock Splits

AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh's most recent stock split took place on November 21, 2022 with a 1:16 split ratio.

Last Split Date11/21/2022
Split Ratio1:16

Scores

As of September 30, 2026, AbbVie, Inc. Shs Unsponsored Brazilian Depository Receipt Repr 0.0625 Sh has an Altman Z-Score of 3.86, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.86